• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
GLP-1 RA prescription trends: January 2018 – June 2025

GLP-1 RA prescription trends: January 2018 – June 2025

by Truveta Research | Jul 24, 2025 | Research

Overall GLP-1 prescribing rates (GLP-1 RA prescriptions per total prescriptions) in June 2025 increased slightly relative to March 2025 (+7.7%). Tirzepatide is now the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and...
GLP-1 RA prescription trends: January 2018 – March 2025

GLP-1 RA prescription trends: January 2018 – March 2025

by Truveta Research | Apr 18, 2025 | Research, Research Insights

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in March 2025 increased relative to December 2024 (+12.96%). Anti-diabetic medication (ADM) prescribing increased from December 2024 to January 2025, then remained relatively stable until March...
Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

Why women experience more GLP-1 side effects: New research from Olio Labs using Truveta Data

by Truveta staff | Apr 1, 2025 | Research

GLP-1 drugs like Ozempic and Zepbound are transforming obesity treatment, yet 40-85% of patients are plagued by adverse GI events—particularly women. New research from Olio Labs, using Truveta Data, reveals that women experience nausea and vomiting at significantly...
GLP-1 RA prescription trends: January 2018 – December 2024

GLP-1 RA prescription trends: January 2018 – December 2024

by Truveta staff | Mar 7, 2025 | Research

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

GLP-1 discontinuation and reinitiation trends study published in JAMA Network Open

by Truveta staff | Jan 31, 2025 | Research

Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
« Older Entries

Share this


Recent posts

  • Truveta experts: Gestational diabetes screening in real-world practice
  • Non-small cell lung cancer: Biomarkers, treatments, and outcomes in real-world data
  • Johns Hopkins builds research community to explore new frontiers in health using Truveta Data

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.